Drugs / IMC-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04748705 | Jun 2021 → Aug 2022 | fibromyalgia | Virios Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01850420 | May 2013 → Jan 2014 | fibromyalgia, myofascial pain syndrome | Innovative Med Concepts, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04748705 ↗ |
| Route | Oral | “Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.” NCT04748705 ↗ |